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7Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, SpainThrombocytopenia (platelet count <150,000/lL) is a common complication in patients with chronic liver disease (CLD)
that has been observed in up to 76% of patients. Moderate thrombocytopenia (platelet count, 50,000/lL–75,000/lL)
occurs in approximately 13% of patients with cirrhosis. Multiple factors can contribute to the development of thrombo-
cytopenia, including splenic platelet sequestration, bone marrow suppression by chronic hepatitis C infection, and antiviral
treatment with interferon-based therapy. Reductions in the level or activity of the hematopoietic growth factor thrombo-
poietin (TPO) may also play a role. Thrombocytopenia can impact routine care of patients with CLD, potentially post-
poning or interfering with diagnostic and therapeutic procedures including liver biopsy, antiviral therapy, and medically
indicated or elective surgery. Therapeutic options to safely and eﬀectively raise platelet levels could have a signiﬁcant eﬀect
on care of these patients. Several promising novel agents that stimulate TPO and increase platelet levels, such as the oral
platelet growth factor eltrombopag, are currently in development for the prevention and/or treatment of thrombocytopenia.
The ability to increase platelet levels could signiﬁcantly reduce the need for platelet transfusions and facilitate the use of
interferon-based antiviral therapy and other medically indicated treatments in patients with liver disease.
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Thrombocytopenia (platelet counts <150,000/lL) is a
common complication in patients with chronic liver dis-
ease (CLD), reported in as many as 76% of cirrhotic
patients [1]. Platelets play an important role in hemosta-
sis that has been the subject of a recent comprehensive
review [2]. The clinical signiﬁcance of mild thrombocy-
topenia (>75,000/lL–<150,000/lL) is minimal and usu-
ally does not interfere with treatment or management
decisions. Moderate thrombocytopenia (50,000/lL–
75,000/lL) is observed in approximately 13% of cir-
rhotic patients. Severe thrombocytopenia (<50,000/lL)
can be associated with signiﬁcant morbidity, often
complicating the medical management of patients withed by Elsevier B V. . Open access under CC BY-NC-ND license.
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bocytopenic purpura (ITP) [5], chronic hepatitis C virus
(HCV) infection [6], and other disorders. Severe throm-
bocytopenia requiring platelet transfusions occurs in 1%
of patients. While mild to moderate thrombocytopenia
rarely leads to spontaneous bleeding during invasive
procedures including liver biopsy [7,8] and liver trans-
plantation [1], severe thrombocytopenia can signiﬁ-
cantly increase the risk of bleeding. Cerebral
hemorrhage or hemorrhage from gastrointestinal (GI)
sources is rare but can be fatal [7,8].
This review focuses on the causes of thrombocytope-
nia, its impact, and its clinical signiﬁcance for routine
patient care. This review also describes some novel treat-
ment options.2. Aetiology, consequences, and approaches to the
evaluation of thrombocytopenia
2.1. Aetiology
In patients with CLD or HCV, the pathogenesis of
thrombocytopenia is multifactorial. Possible causes
include splenic sequestration of platelets, suppression
of platelet production in the bone marrow, and
decreased activity of the hematopoietic growth factor
thrombopoietin (TPO) (Fig. 1). Historically, thrombo-
cytopenia was thought to arise from increased pooling
of platelets in the enlarged spleen due to portal hyper-
tension [9,10]. However, treatments aimed at reversing
portal hypertension do not always correct thrombocyto-
penia, and decreased platelet production has been noted
in patients without hypersplenism [11], suggesting that
other factors are involved. Increased destruction of
platelets within the spleen, intrasplenic production of
autoantibodies, and plasma expansion resulting in
hemodilution can also contribute to thrombocytopenia
as well as other cytopenias [10]. However, the absolute
platelet number is not the only variable since there is
also a degree of thrombocytopathy due to defective
thromboxane A2 synthesis and abnormalities of the
platelet glycoprotein Ib [2]. There is a resulting increase
in the bleeding time in 40% of cirrhotic patients, the clin-
ical signiﬁcance of which is unknown and it is also
unclear whether platelet factors can account for the pro-
longed bleeding time. Tripodi et al. have, in fact, sug-
gested that traditional tests to determine the risk of
hemorrhage such as bleeding time may have little role
in the evaluation of bleeding risk in cirrhotic patients [2].
Suppression of platelet production in the bone mar-
row is also multifactorial and can be caused by the
underlying aetiology of the liver disease (e.g., HCV or
alcohol) [12,13]. In CLD patients, autoantibodies direc-
ted against platelet surface antigens can enhance
removal of platelets by the splenic and hepatic reticulo-endothelial systems and trigger their rapid destruction,
as observed in chronic ITP [14]. In one small study of
patients with chronic HCV, an increased prevalence of
ITP was observed [15].
It is well established that antiviral therapy with inter-
feron alfa (IFN-a) induces thrombocytopenia, necessi-
tating dose reductions [16]. In two recent studies of
patients with HCV, downward dose modiﬁcations were
required in up to 6% of patients treated with PEG-IFN
[17,18] and this is even more common in patients with
HCV-related cirrhosis in which dose modiﬁcation and
discontinuation were necessary in 19% and 2% of
patients, respectively [19]. Dose modiﬁcation of IFN
due to thrombocytopenia and other hematological com-
plications may result in a reduction in sustained virolog-
ical response (SVR) [20].
2.2. Thrombocytopenia and coagulopathies of liver disease
Coagulopathies, deﬁned as defects in clotting, are
commonly observed in patients with decompensated cir-
rhosis and acute liver failure. Coagulopathy often results
from liver damage and/or loss of liver synthetic func-
tion, leading to diminished capacity to produce clotting
factors (e.g., factors I (ﬁbrinogen), II (prothrombin), V,
VII, IX, X, XI, protein C, and antithrombin) and
increased bleeding risk. Platelets have a dual role in
hemostasis. During primary hemostasis, platelets adhere
to the subendothelium at the site of liver injury through
the adhesive protein von Willebrand factor (vWF) and
then platelets aggregate with each other through vWF
and/or ﬁbrinogen, producing the platelet plug. Recent
observations suggest that patients with chronic liver dis-
ease have elevated levels of vWF [21] and that increased
vWF may at least partially compensate for decreased
numbers of platelets and/or reduced functional capacity.
During secondary hemostasis (coagulation), platelets
expose on their surface negatively charged phospholip-
ids that act as receptors for the plasmatic coagulation
factors, thus triggering thrombin generation, ﬁbrin for-
mation, and platelet plug stabilization.
The current therapeutic approach is to identify the
deﬁcient factors contributing to coagulopathy and
replace these deﬁcient factors using platelets, fresh-fro-
zen plasma, or cryoprecipitates as appropriate [22,23].
2.3. Role of TPO
TPO is a potent cytokine that regulates megakaryo-
cyte and platelet production. TPO, produced primarily
in the liver but also in the bone marrow and kidney,
binds to the TPO receptor (TPO-R) expressed on the
surface of stem cells, megakaryocyte progenitor cells,
megakaryocytes, and platelets. TPO acts at all stages
of thrombopoiesis to regulate the development and mat-
uration of megakaryocytes and subsequent release of
Fig. 1. Multiple factors can cause or contribute to the development of thrombocytopenia in patients with chronic liver disease. These include portal
hypertension with resulting hypersplenism, cirrhosis, hepatocellular carcinoma and chemotherapy, anti-platelet antibodies, decreased levels or activity of
the platelet growth factor thrombopoietin, and bone marrow suppression of thrombopoiesis due to antiviral therapy (e.g., IFN) and/or direct
myelosuppressive eﬀects of HCV infection.
1002 N. Afdhal et al. / Journal of Hepatology 48 (2008) 1000–1007platelets (Fig. 2) [24,25]. Depending on the stage of
megakaryopoiesis, TPO can synergize with other cyto-
kines such as IL-3, IL-11, erythropoietin, and granulo-
cyte colony-stimulating factor (G-CSF) to promote
megakaryocyte proliferation and diﬀerentiation and ery-
throid development. Additionally, TPO enhances plate-
let activation and function.
Decreases in the level and/or activity of TPO may
play a role in the pathogenesis of thrombocytopenia.
In healthy subjects, circulating TPO levels are inversely
related to platelet count. Cirrhotic patients with throm-
bocytopenia have lower circulating TPO levels than cir-
rhotic patients with normal platelet counts, possibly as a
result of diminished TPO production. Response to TPO
may also be blunted in these patients [26]. Followingsuccessful liver transplantation or splenic embolization,
TPO levels appear to normalize, suggesting that
increased TPO degradation by platelets sequestered in
the spleen may also contribute to thrombocytopenia in
cirrhotic patients [27].3. Clinical signiﬁcance and sequelae of thrombocytopenia
Thrombocytopenia has been used as a marker of
advanced liver ﬁbrosis and portal hypertension for many
years, but surprisingly little is known about the clinical
signiﬁcance of low counts. In particular, little is known
about the impact of thrombocytopenia on either intrace-
rebral bleeding or variceal bleeding in cirrhosis [28–31].
Fig. 2. Role of thrombopoietin in megakaryopoiesis and thrombopoiesis.
Thrombopoietin has a central role in regulating the megakaryocyte
maturation and development, acting at all stages of megakaryopoiesis. In
concert with other hematopoietic cytokines and growth factors such as
interleukin (IL)-3, IL-6, IL-11, erythropoietin, granulocyte colony-
stimulating factor (G-CSF), leukemia inhibitory factor, and steel factor,
thrombopoietin promotes the growth and diﬀerentiation of megakaryo-
cytes from bone marrow progenitor cells, culminating in the production
and release of platelets. Reprinted with permission from Kaushansky K,
N Engl J Med 1998;339:746–754.
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CLD patients often require numerous medical proce-
dures during diagnosis and therapy (Table 1) and the
presence of thrombocytopenia can signiﬁcantly compli-
cate routine patient care for these patients resulting in
delayed or cancelled procedures. While liver biopsies
in CLD patients are generally associated with a low
(0.3%) risk of bleeding complications [32], the number
of procedures postponed due to concern over such pos-
sible complications is unknown. Many physicians
require platelet counts ofP80,000/lL to safely perform
a percutaneous liver biopsy, but the data on the safety of
laparoscopic and transjugular liver biopsies suggests
that few complications occur with a platelet count above
50,000/lL [33–36].
In a retrospective analysis of 608 large-volume para-
centesis (LVP) or thoracentesis procedures, the risk of
bleeding complications was not elevated in patients with
mild to moderate thrombocytopenia or mild coagulopa-
thies [37]. However, hemoglobin decreases occurred in
8% of patients with severe thrombocytopenia compared
with only 3% of patients with platelet counts P50,000/
lL. In 628 thrombocytopenic patients (513 with cirrho-
sis) undergoing LVP, no signiﬁcant complications were
noted [38]. In a study in which 4729 patients with liver
disease-related ascites underwent abdominal paracente-
sis, severe bleeding occurred in <0.2% of procedures
and was unrelated to platelet count or elevated INR
(international normalized ratio) [39]. All available data
suggest that the invasive procedures (e.g., liver biopsy,
large-volume parancentesis, thoracentesis, and dental
procedures) may be performed in patients with platelet
counts P50,000/lL with little risk of bleeding. There
is no consensus on the safety of procedures in patients
with platelet counts 620,000/lL. Guidelines are clearly
needed to guide the practitioner.5. Evidence-based therapy
Current treatment options for severe thrombocytope-
nia include platelet transfusion, splenic artery emboliza-
tion, splenectomy, and placement of a transjugular
intrahepatic portosystemic stent shunt (TIPSS).
Patients with platelet counts below 50,000/lL may
beneﬁt from prophylactic transfusions to increase plate-
let counts above 50,000/lL before procedures. Guide-
lines for when to use platelet transfusions are
available, but the relevance of these published guidelines
for CLD patients is unclear. The American Society of
Clinical Oncology recommends platelet transfusions
for cancer patients with platelet counts of 10,000/lL–
20,000/lL, depending on the type of cancer [41]. Cur-
rently, there is no consensus on the appropriate thresh-
old values for prophylactic platelet transfusions in CLD
Table 1
Risk of bleeding or worsened thrombocytopenia with medical procedures/therapies in patients with thrombocytopenia, malignancies, and/or chronic liver
disease
Procedure Patient population studied Comments
Liver biopsy
 Percutaneous liver biopsy [33]
 Laparoscopic liver biopsy [34,35]
 Transjugular liver biopsy [36]
291 patients with mild hemostatic abnormalities Bleeding risk greatest in patients with
malignancy50 procedures in each of 2 studies
50 patients with severe thrombocytopenia
Paracentesis/thoracentesis [37–39] 608 procedures in patients with mild to moderate
thrombocytopenia [37]; 628 thrombocytopenic
patients (513 with cirrhosis) [38]; 4729 patients
with liver disease-related ascites [39]
Low risk of bleeding complications if platelets
>50,000/lL
IFN-based HCV antiviral therapy IFN therapy causes reductions in platelet counts
in chronic HCV patients with and without
cirrhosis [26]
Recommendations from AGA [5]: dose
reduction of PEG-IFN-a2a for platelets
25,000–50,000/lL, discontinuation if
<25,000/lL
Dose reduction of PEG-IFN-a2b for platelets
680,000/lL, discontinuation if 650,000/lL
Dental procedures [40] 142 dental extractions in patients with
hematologic malignancies
Thrombocytopenia (platelet counts <100,000/
lL) occurred in 80/142 extractions
Various medically indicated procedures
 Cosmetic, emergency, or elective surgery
 Prostate biopsy
 Polypectomy/cholecystectomy
Low level of bleeding risk that may
complicate and/or require postponement of
scheduled procedures
PT, prothrombin time.
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<20,000/lL, <50,000/lL, or <100,000/lL), depending
on the clinical setting and procedure planned. While
low cut-oﬀ values (<10,000/lL) may be appropriate
for uncomplicated thrombocytopenic patients, other
patients (e.g., postsurgery or those with high fever,
splenomegaly, or infection) often require higher platelet
transfusion triggers (<50,000/lL or <100,000/lL)
[42,43]. Complications and limitations of platelet trans-
fusion include febrile nonhemolytic and allergic reac-
tions, need for hospitalization, iron overload (with
chronic transfusions), risk of infection, platelet refracto-
riness due to HLA alloimmunization (occurring in up to
40% of patients), and cost [44,45]. Furthermore, platelet
transfusions do not ensure a hemostatic platelet level,
especially when the risk of bleeding is highest [41].
Splenic artery embolization and splenectomy are
often, but not always, eﬀective in increasing platelet
counts in patients with portal hypertension. Possible
complications of these procedures include splenic
abscesses and portal vein thrombosis. TIPSS placement
can decrease sinusoidal portal pressure, but it is unclear
if portal decompression can reduce the degree of throm-
bocytopenia in cirrhotic patients [46,47].6. Agents targeting the TPO receptor
The central role TPO plays in regulating thrombopoi-
esis and the observed alterations in TPO production or
activity in patients with CLD suggest that TPO canserve as a rational therapeutic target to stimulate plate-
let production. Research has focused on developing
compounds speciﬁcally to stimulate TPO activity in
order to prevent or treat thrombocytopenia in CLD
and other diseases. Several types of TPO agonists and
targeted agents have been evaluated, including IL-11,
recombinant TPO, TPO mimetics, and other agents
(Table 2).
6.1. IL-11
Interleukin-11, normally produced by bone marrow
stromal cells, stimulates megakaryocyte maturation and
platelet production. Subcutaneous injection of recombi-
nant human IL-11 (rhIL-11) stimulates progenitor stem
cells and production of megakaryocytes and platelets,
decreasing the incidence of severe thrombocytopenia.
An open-label, phase II trial evaluated rhIL-11 in combi-
nation with IFN in 13 previously treated or treatment-
naı¨ve HCV patients with low platelet counts (30,000/
lL–100,000/lL) [48]. All 10 patients who completed at
least 24 weeks of therapy maintained platelet counts
>40,000/lL, with increases observed as early as week 2.
HCV viral load decreased signiﬁcantly throughout
treatment. rhIL-11 has been approved by the FDA for
prevention of severe thrombocytopenia following myelo-
suppressive chemotherapy for solid tumors. rhIL-11 can
cause signiﬁcant toxicities, including edema, ﬂuid reten-
tion, and cardiovascular events, and in some studies,
myalgias and arthralgias, and it is relatively costly (esti-
mated $5328 over a 3-week cycle of chemotherapy) [49].
Table 2
Investigational TPO-R agonists for treatment of TCP in CLD
Agent Class Activity Status
rhIL-11 Recombinant human
interleukin-11
Modest increase in platelet counts,
but can be associated with signiﬁcant
toxicity and high cost
Approved for prevention of severe
TCP following myelosuppressive
chemotherapy for solid tumors
Eltrombopag Small-molecule platelet
growth factor
Dose-dependent increase in platelet
counts, allowing initiation of HCV
antiviral therapy
Phase II/III
rhTPO Recombinant human
thrombopoietin
Dose-dependent stimulation of
thrombopoiesis and
megakaryopoiesis
Clinical development halted
PEG-rHuMGDF Pegylated recombinant human
megakaryocyte growth and
development factor
Stimulates thrombopoiesis and
megakaryopoiesis, and enhances
platelet recovery from chemotherapy
Clinical development halted due to
neutralizing anti-TPO antibodies
Promegapoietin TPO agonist Increase in platelet counts when
administered before chemotherapy
Clinical development halted due to
neutralizing anti-TPO antibodies
NIP-004, AMG 531,
AKR-501
TPO mimetics Platelet responses observed with
some agents to date
Phase I/II
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potent thrombopoietic activity and can stimulate plate-
let production. Their clinical utility has been severely
limited by signiﬁcant proinﬂammatory properties that
induce ﬂu-like symptoms including hypotension, fati-
gue, and myalgias [50].
6.2. Eltrombopag
Eltrombopag is a small-molecule nonpeptide oral
platelet growth factor that acts as a TPO-R agonist.
Binding of eltrombopag to the transmembrane domain
of the TPO receptor activates intracellular signal trans-
duction pathways that stimulate megakaryocyte prolif-
eration and diﬀerentiation and increase platelet counts
in a dose-dependent manner in healthy subjects and
patients with chronic ITP [51,52].
A phase II multicenter, randomized trial of daily
eltrombopag in patients with HCV-associated thrombo-
cytopenia and compensated liver disease showed that
after 4 weeks of therapy, platelet count increases to
P100,000/lL were achieved in 75%, 79%, and 95% of
patients treated with 30 mg, 50 mg, and 75 mg eltrombo-
pag, respectively, compared to 0% of placebo patients
(P < 0.001) [53]. Signiﬁcantly more patients in the
eltrombopag treatment groups (36%, 53%, and 65% in
the 30-mg, 50-mg, and 75-mg groups) completed 12
weeks of antiviral therapy compared with 6% of placebo
patients and 75% of these patients had platelet counts
above baseline values at the end of the antiviral treat-
ment phase.
6.3. Recombinant TPO and other thrombopoietic agents
Two forms of recombinant human thrombopoietin
have been evaluated in clinical trials and shown to
increase megakaryopoiesis and thrombopoiesis: recom-binant human TPO (rhTPO) and pegylated recombinant
human megakaryocyte growth and development factor
(PEG-rHuMGDF). rhTPO is a genetically engineered,
full-length, glycosylated form of thrombopoietin that
can signiﬁcantly increase platelet counts, but reduction
of thrombocytopenia is not always accompanied by a
decrease in platelet transfusions [54].
PEG-rHuMGDF is an N-terminal TPO derivative
that is pegylated to extend its half-life and retain TPO
activity [25,55]. In initial trials in patients undergoing
chemotherapy, PEG-rHuMGDF treatment increased
median platelet nadir counts and enhanced recovery in
a dose-dependent manner [56–58]. Phase II trials dem-
onstrated promising results for mobilization prior to
stem cell transplantation [25]. However, some subjects
including normal platelet donors treated with PEG-rHu-
MGDF developed neutralizing antibodies that cross-
reacted with and inactivated endogenous TPO, resulting
in severe thrombocytopenia, which resulted in termina-
tion of clinical development of this drug [54].
Various other thrombopoietic compounds are in the
early stages of clinical development for the treatment of
thrombocytopenia. TPO mimetics (e.g., NIP-004, AMG
531, and AKR-501) are small molecules that bind to
and activate the TPO receptor, but because they do not
share sequence homology with TPO should not trigger
an antigenic reaction [55,59,60]. The clinical potential of
these agents in the treatment of thrombocytopenia in
CLD patients remains to be determined.7. Conclusions
Thrombocytopenia can adversely aﬀect treatment of
CLD, limiting the ability to administer therapy and
delaying planned surgical/diagnostic procedures because
of an increased risk of bleeding. The development of
1006 N. Afdhal et al. / Journal of Hepatology 48 (2008) 1000–1007consensus guidelines deﬁning threshold platelet counts
in CLD patients below which procedures should be
delayed or below which platelet transfusions or plate-
let-stimulating agents should be utilized needs to be
deﬁned. Novel TPO-R agonists including eltrombopag
have a signiﬁcant potential as both therapy and prophy-
laxis in various clinical settings for patients with CLD
and require further clinical investigation.Acknowledgement
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